Data reassuring on saxagliptin CV safety

摘要

Diabetes medicine saxagliptin is not associated with an increased risk of ischaemic cardiovascular events, according to a postmarketing study reported last month at the European Society of Cardiology annual congress (New England Journal of Medicine, 2 September 2013).